Revue Francaise d Allergologie最新文献

{"title":"Quoi de neuf en allergologie pédiatrique en 2025 ?","authors":"T. Chapron,&nbsp;R. Saniour,&nbsp;M. Braire-Bourrel,&nbsp;S. Atmani-Henry,&nbsp;A. Nosbaum,&nbsp;M.-A. Lefevre","doi":"10.1016/j.reval.2026.105064","DOIUrl":"10.1016/j.reval.2026.105064","url":null,"abstract":"<div><div>This review highlights selected publications from 2025 in pediatric allergology with potential implications for clinical practice. In severe pediatric asthma, the expanding use of biologic therapies supports a phenotype- and comorbidity-driven approach, although reliable predictive biomarkers remain unavailable to guide treatment selection. In atopic dermatitis, tapinarof emerges as a promising new non-steroidal topical option for children. In pediatric eosinophilic esophagitis, a milk-only elimination diet appears to provide histological efficacy comparable to a more restrictive diet, with better acceptability. In food allergy, epitope-specific IgE and IgG4 antibodies represent promising biomarkers for predicting the natural history of peanut allergy, although their use remains limited to research settings. Recent data on food protein-induced enterocolitis syndrome highlight the influence of regional complementary feeding practices on triggering foods. Finally, a survey among childcare professionals shows that individualized healthcare plans alone are insufficient to ensure the safety of food-allergic children without regular practical training in anaphylaxis recognition and adrenaline auto-injector use. Overall, these studies illustrate the evolution of pediatric allergology toward more personalized, progressive, and pragmatic care.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 5","pages":"Article 105064"},"PeriodicalIF":0.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149154052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quoi de neuf en allergologie… ? Faire le tri dans une littérature toujours plus abondante","authors":"A. Didier","doi":"10.1016/j.reval.2026.105068","DOIUrl":"10.1016/j.reval.2026.105068","url":null,"abstract":"","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 5","pages":"Article 105068"},"PeriodicalIF":0.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149051714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quoi de neuf en allergologie respiratoire en 2025 ?","authors":"E. Losseff,&nbsp;L. Masternak,&nbsp;M. Braire-Bourrel,&nbsp;M. Gaillot-Drevon,&nbsp;C. Egeley,&nbsp;B. Pascal,&nbsp;A. Nosbaum,&nbsp;M.-A. Lefevre","doi":"10.1016/j.reval.2026.105065","DOIUrl":"10.1016/j.reval.2026.105065","url":null,"abstract":"<div><div>This review highlights selected recent publications in respiratory allergology with potential implications for clinical practice. In preterm infants, respiratory syncytial virus prophylaxis may be associated with a lower risk of subsequent aeroallergen sensitization, although a causal relationship cannot be established. Allergen immunotherapy retains a distinctive role through its effect on the allergen-specific immune response, with encouraging data in controlled allergic asthma and, more cautiously, in selected patients with previously stabilized severe asthma. In severe asthma, switching biologic therapy in cases of insufficient response underlines the value of a strategy based on the inflammatory phenotype and type 2 comorbidities. Finally, the associations between asthma, obstructive sleep apnea syndrome and bronchiectasis emphasize the importance of a comprehensive assessment of the respiratory phenotype. Overall, these studies illustrate a respiratory allergology field that is becoming more preventive, personalized and attentive to comorbidities.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 5","pages":"Article 105065"},"PeriodicalIF":0.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149154051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exanthème intertrigineux symétrique lié à une intoxication aiguë au fréon : rapport d’un cas original","authors":"A. Zaim ,&nbsp;Z. Douhi ,&nbsp;I. Warsama Abib ,&nbsp;M. Soughi ,&nbsp;S. Elloudi ,&nbsp;H. Baybay ,&nbsp;F.Z. Mernissi","doi":"10.1016/j.reval.2026.105034","DOIUrl":"10.1016/j.reval.2026.105034","url":null,"abstract":"<div><div>Cutaneous manifestations related to chlorofluorocarbons, particularly freon, are rare and are most often limited to contact lesions such as xerosis, dermatitis, or frostbite. Diffuse eruptions remain exceptional and poorly described. We report an original case of symmetrical intertriginous exanthema occurring in the context of accidental acute freon poisoning. A 38-year-old man presented with neurological and respiratory symptoms following domestic exposure to a defective refrigerator. Four days after exposure, a pruritic eruption appeared, initially involving the antecubital and axillary folds and subsequently extending to the flanks and inguinal regions. Clinical examination revealed bilateral, symmetric intertriginous erythematous plaques surmounted by non-follicular pustules, sparing the face, palms, soles, and mucous membranes. Laboratory investigations were normal, and no recent drug intake was reported. The diagnosis of symmetrical intertriginous exanthema secondary to acute freon poisoning was established based on clinical history and temporal association. Removal of the toxic source, combined with topical corticosteroids and antihistamines, led to complete resolution within four days. This case highlights that acute freon poisoning may induce atypical cutaneous eruptions mimicking drug-induced toxicoderma and should be recognized as an exceptional environmental cause of exanthema.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 4","pages":"Article 105034"},"PeriodicalIF":0.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148357680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nouvelles recommandations pour la prévention de l’asthme et de l’allergie : l’EAACI se met au vert !","authors":"A. Didier","doi":"10.1016/j.reval.2026.105035","DOIUrl":"10.1016/j.reval.2026.105035","url":null,"abstract":"","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 4","pages":"Article 105035"},"PeriodicalIF":0.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148442155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge and awareness of pollen-food allergy syndrome among dentists: A cross-sectional survey","authors":"K.O. Dolu,&nbsp;S. Arslan,&nbsp;E. Arslan","doi":"10.1016/j.reval.2026.105036","DOIUrl":"10.1016/j.reval.2026.105036","url":null,"abstract":"<div><h3>Background and objective</h3><div>This cross-sectional survey represents the first study to systematically quantify pollen-food allergy syndrome (PFAS) awareness and clinical management approaches among actively practising dentists.</div></div><div><h3>Methods</h3><div>Seventy-seven dentists in Istanbul, Turkey participated (mean age 34.4<!--> <!-->±<!--> <!-->7.9 years; 72.7% female) in this cross-sectional, descriptive survey. The survey was distributed via an open link through professional messaging and social media platforms; accordingly, a response rate could not be calculated.</div></div><div><h3>Results</h3><div>Nearly all participants (97.4%) had received no postgraduate allergy training, and 94.8% reported inadequate or absent PFAS awareness. A critical recognition–application gap was identified: 62.3% selected the correct definition from multiple-choice options, yet only 37.7% correctly interpreted an equivalent clinical scenario involving raw versus cooked food reactions – and notably, 41.7% of those who correctly identified the definition still failed this scenario. More strikingly, 93.5% had never considered PFAS in differential diagnosis despite 54.5% reporting encounters with oral mucosal complaints in the preceding year. PFAS knowledge showed no association with professional experience, specialty, or prior patient encounters (all <em>P</em> <!-->&gt;<!--> <!-->0.05), indicating a systemic educational deficit rather than an experience-dependent gap. Conversely, 71.4% correctly identified allergy and immunology as the appropriate referral specialty, and 81.8% rated their educational need at the highest level.</div></div><div><h3>Conclusions</h3><div>These findings reveal that PFAS remains a diagnostically invisible syndrome in dental practice. Given dentists’ frontline position in encountering oral mucosal symptoms – the hallmark presentation of PFAS – integration of allergic syndromes into dental curricula, structured allergist–dentist referral pathways, and practical screening protocols are urgently needed.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 4","pages":"Article 105036"},"PeriodicalIF":0.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148566446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prurigo strophulus chez l’enfant : profil épidémiologique, clinique et prise en charge au centre hospitalier universitaire d’Oujda","authors":"S. Moujahid ,&nbsp;O. Hormi ,&nbsp;L. El Yamani ,&nbsp;S. Denna ,&nbsp;N. Zerrouki ,&nbsp;N. Zizi","doi":"10.1016/j.reval.2026.104721","DOIUrl":"10.1016/j.reval.2026.104721","url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>Le prurigo strophulus est une dermatose prurigineuse fréquente chez l’enfant, souvent déclenchée par des piqûres d’insectes. Elle se caractérise par des papules excoriées, un prurit intense et peut altérer la qualité de vie de l’enfant et de sa famille.</div></div><div><h3>Objectifs</h3><div>Décrire le profil épidémiologique et clinique du prurigo strophulus chez les enfants pris en charge au CHU d’Oujda et analyser les modalités de traitement utilisées.</div></div><div><h3>Méthodes</h3><div>Il s’agit d’une étude rétrospective menée sur une période de 5 ans, incluant tous les enfants diagnostiqués avec prurigo strophulus. Les données démographiques, cliniques et thérapeutiques ont été recueillies à partir des dossiers médicaux.</div></div><div><h3>Résultats/discussions</h3><div>Cent vingt enfants ont été inclus dans l’étude, avec une légère prédominance masculine (sexe-ratio H/F<!--> <!-->=<!--> <!-->1,2) et un âge moyen de 4,8<!--> <!-->±<!--> <!-->2,1 ans. La majorité des enfants (62 %) avaient moins de 5 ans. Une atopie personnelle était retrouvée chez 48 % des patients et une atopie familiale chez 29 %. La saison estivale était la plus représentée (54 % des cas), suggérant un rôle important des piqûres d’insectes. Cliniquement, les lésions étaient principalement localisées sur les membres inférieurs (75 %), suivis du tronc (48 %) et du visage (22 %). Les papules excoriées étaient présentes chez 100 % des enfants et un prurit modéré à sévère (EVA<!--> <!-->≥<!--> <!-->5) était rapporté dans 68 % des cas. Dans 40 % des cas, le pruritus nocturne entraînait des réveils fréquents et une perturbation du sommeil. Concernant la prise en charge, tous les enfants ont reçu des antihistaminiques oraux de deuxième génération, avec une augmentation des doses par palier chez 37 % des patients présentant un prurit sévère. Des dermocorticoïdes topiques ont été prescrits chez 82 % des enfants, avec un soulagement rapide des lésions dans 70 % des cas. Des mesures préventives, telles que l’usage de répulsifs et le port de vêtements protecteurs, ont été recommandées chez 45 % des patients. L’évolution a été favorable dans 88 % des cas, avec résolution des lésions en 2 à 4 semaines.</div></div><div><h3>Conclusion</h3><div>Le prurigo strophulus est une dermatose fréquente chez l’enfant. Une prise en charge précoce permet une résolution rapide et améliore le confort des enfants et de leur famille.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104721"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147611988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction précoce et régulière des allergènes alimentaires lors de la diversification : étude des pratiques parentales et de l’impact d’un programme « clé en main »","authors":"C. Desclée De Maredsous ,&nbsp;G. Benoist ,&nbsp;D. Sabouraud-Leclerc ,&nbsp;G. Lezmi ,&nbsp;A. Lemoine","doi":"10.1016/j.reval.2026.104726","DOIUrl":"10.1016/j.reval.2026.104726","url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>Les recommandations de prévention primaire des allergies alimentaires encouragent une introduction précoce (dès 4 à 6 mois) et régulière (2<!--> <!-->g de protéines de chaque allergène/semaine en plusieurs prises) des allergènes majeurs.</div></div><div><h3>Objectifs</h3><div>Cette étude visait à évaluer l’impact sur les pratiques de diversification alimentaire du programme Dalipo®, facilitant l’introduction de l’arachide et des fruits à coque, selon les recommandations.</div></div><div><h3>Méthodes</h3><div>Un questionnaire en ligne a été adressé à des parents de nourrissons âgés de 10 à 24 mois pour déterminer les modalités d’introduction des allergènes majeurs et la survenue d’allergies à ces aliments. Le groupe témoin (<em>n</em> <!-->=<!--> <!-->304) a été diversifié selon les pratiques familiales. Dans le groupe berlingots (<em>n</em> <!-->=<!--> <!-->102), l’arachide, l’amande, la noisette et la noix de cajou étaient introduites progressivement et successivement sous forme d’unidoses (de 0,1<!--> <!-->g à 1<!--> <!-->g de protéines/allergène, jusqu’à 2<!--> <!-->×<!--> <!-->1<!--> <!-->g/semaine).</div></div><div><h3>Résultats/discussions</h3><div>Dans le groupe témoin, respectivement 27 %, 27 %, 33 % et 62 % des enfants n’avaient pas consommé d’arachide, d’amande, de noisette ou de noix de cajou avant 1 an, contre 0-3 % dans le groupe berlingots (<em>p</em> <!-->&lt;<!--> <!-->0,001). Parmi les familles ayant introduit ces 4 allergènes, l’introduction à 4–6 mois était plus fréquente dans le groupe berlingots (65–68 % vs 52–58 % ; <em>p</em> <!-->&lt;<!--> <!-->0,05). Dans le groupe témoin, 35 % des parents déclarent avoir donné des quantités significatives (≥<!--> <!-->1 cuillère à café) contre 96 % dans le groupe berlingots (<em>p</em> <!-->&lt;<!--> <!-->0,001). Dans le groupe berlingots, 88 % des enfants consommaient ces allergènes au moins une fois/semaine, contre 21 à 27 % dans le groupe témoin (<em>p</em> <!-->&lt;<!--> <!-->0,001). Trois allergies alimentaires diagnostiquées médicalement ont été rapportées (1 dans le groupe berlingots, 2 dans le groupe témoin – dont 1 réaction anaphylactique –, <em>p</em> <!-->=<!--> <!-->0,9).</div></div><div><h3>Conclusion</h3><div>Le programme Dalipo® améliore l’adhésion aux recommandations en termes d’âge d’introduction, de quantités consommées et de régularité d’exposition, sans augmentation du risque de réaction allergique. Ce type d’outil apparaît prometteur pour la prévention primaire des allergies alimentaires chez l’enfant.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104726"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quand le « naturel » devient toxique : dermatite bulleuse sévère à l’arnica chez un enfant","authors":"L. Benahmed ,&nbsp;S. Denna ,&nbsp;N. Zerrouki ,&nbsp;N. Zizi","doi":"10.1016/j.reval.2026.104725","DOIUrl":"10.1016/j.reval.2026.104725","url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>Les préparations traditionnelles à base de plantes restent largement utilisées au Maroc, souvent considérées comme des remèdes miracles pour toutes sortes d’indications. Perçues comme « naturelles » et donc inoffensives, elles peuvent néanmoins contenir des substances fortement allergisantes ou irritantes. Leur application sous occlusion peut augmenter la pénétration cutanée et aggraver la sévérité des réactions inflammatoires.</div></div><div><h3>Objectifs</h3><div>Décrire un cas de dermatite de contact bulleuse sévère induite par une préparation traditionnelle à base d’arnica chez un enfant.</div></div><div><h3>Méthodes</h3><div>Observation clinique documentée, complétée par une exploration allergologique par tests épicutanés.</div></div><div><h3>Résultats/discussions</h3><div>Un garçon de 13 ans, sans antécédents pathologiques notables, consulte aux urgences pour un placard érythémateux, prurigineux et douloureux du dos du pied droit, apparu trois jours après un traumatisme mineur lors d’un match de football. L’anamnèse retrouvait l’application, par la mère, d’une crème traditionnelle dite « contre l’eczéma », composée de plantes broyées et maintenue sous occlusion sur le site du choc pour soulager la douleur. Dans les 48<!--> <!-->heures suivant l’application, l’enfant a développé une dermatite aiguë caractérisée par un érythème inflammatoire œdémateux et des vésiculo-bulles limitées à la zone de contact. Une dermatite de contact aiguë a été suspectée. L’arrêt du produit et l’instauration d’un dermocorticoïde topique ont permis une évolution favorable en 72<!--> <!-->heures. Le bilan allergologique secondaire montrait une positivité des patch-tests à Arnica montana, riche en lactones sesquiterpéniques, confirmant une dermatite de contact allergique, probablement majorée par l’effet occlusif. L’arnica est une cause connue de dermatite de contact allergique retardée. Les préparations artisanales en contiennent souvent à des concentrations non contrôlées. L’occlusion augmente la pénétration cutanée et favorise les formes aiguës sévères, particulièrement chez l’enfant dont la barrière cutanée est plus perméable.</div></div><div><h3>Conclusion</h3><div>Ce cas illustre le risque de dermatite de contact aiguë lié à l’utilisation non encadrée de produits à base de plantes, particulièrement sous occlusion, souvent considérés à tort comme inoffensifs.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104725"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of up to 3 years of dupilumab treatment in infants and children with severe atopic dermatitis","authors":"A.S. Paller ,&nbsp;A. Taïeb ,&nbsp;S. Weidinger ,&nbsp;M. Futamura ,&nbsp;X.H. Gao ,&nbsp;L.F. Eichenfield ,&nbsp;Y. Ma ,&nbsp;R. Prescilla ,&nbsp;T.V. Nguyen","doi":"10.1016/j.reval.2026.104709","DOIUrl":"10.1016/j.reval.2026.104709","url":null,"abstract":"<div><h3>Prerequisites/context</h3><div>Patients with severe atopic dermatitis (AD) are associated with greater disease burden and worse quality of life than those with mild-to-moderate disease. Dupilumab has shown acceptable safety and sustained efficacy for up to 2 years in infants and children with moderate-to-severe AD.</div></div><div><h3>Objectifs</h3><div>We report long-term (up to 3 years) safety and efficacy of dupilumab in pediatric patients with severe AD.</div></div><div><h3>Methods</h3><div>Children (6 months [mo]–11 years [yr]) with severe AD (Investigator's Global Assessment score of 4) from prior studies (<span><span>NCT03346434</span><svg><path></path></svg></span>, <span><span>NCT03345914</span><svg><path></path></svg></span>) were administered dupilumab (200<!--> <!-->mg q4w for body weight 5 to<!--> <!-->&lt;<!--> <!-->15<!--> <!-->kg, 300<!--> <!-->mg q4w for 15 to<!--> <!-->&lt;<!--> <!-->30<!--> <!-->kg, 200<!--> <!-->mg q2w for 30 to<!--> <!-->&lt;<!--> <!-->60<!--> <!-->kg, or 300<!--> <!-->mg q2w for<!--> <!-->≥<!--> <!-->60<!--> <!-->kg) in an open-label extension study (LIBERTY AD PED-OLE [<span><span>NCT02612454</span><svg><path></path></svg></span>]). Topical treatments were allowed. SCORing Atopic Dermatitis (SCORAD) score, SCORAD-50, and body surface area (BSA) were assessed through Week 152.</div></div><div><h3>Results/discussions</h3><div>Of 125 patients, 62.0% (<em>n</em> <!-->=<!--> <!-->31/50) aged 6 mo–5 yr and 66.7% (<em>n</em> <!-->=<!--> <!-->50/75) aged 6–11 yr completed 152 weeks of treatment with mean treatment exposure (SD) of 124.2 (48.6) and 116.0 (48.5) weeks, respectively. Treatment-emergent adverse events (TEAEs) (mostly mild or moderate) occurred in 86.0% (in 6 mo–5 yr) and in 89.3% (in 6–11 yr). In both groups, the most frequent TEAEs were conjunctivitis (4.0%, 4.0%), upper respiratory tract infection (2.0%, 4.0%) and blepharitis (2.0%, 2.7%). SCORAD scores reduced from 73.1 to 20.8 (in 6 mo–5 yr) and 73.9 to 22.7 (in 6–11 yr). SCORAD-50 was achieved by<!--> <!-->&gt;<!--> <!-->80% patients (<em>n</em> <!-->=<!--> <!-->27/31 in 6 mo–5 yr and <em>n</em> <!-->=<!--> <!-->42/50 in 6–11 yr) by week 152. Across all SCORAD components, the proportion of patients with moderate or severe scores reduced from parent study baseline (52–100%) to week 152 (0–25%; 33–38% of patients had missing data at week 152). Mean affected BSA reduced from 55.6 to 14.2 (in 6 mo–5 yr), and 62.4 to 8.9 (in 6–11 yr).</div></div><div><h3>Conclusion</h3><div>An acceptable and consistent long-term safety profile was demonstrated for up to 3 years of dupilumab treatment in infants and children with severe AD. Moderate and severe scores for all SCORAD components generally improved to absent or mild, reflecting reduced intensity across all AD signs.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104709"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}